


# Neuron

## Sodium Channel *SCN3A* ( $\text{Na}_v1.3$ ) Regulation of Human Cerebral Cortical Folding and Oral Motor Development

### Graphical Abstract



### Authors

Richard S. Smith, Connor J. Kenny, Vijay Ganesh, ..., Anna-Elina Lehesjoki, Christopher A. Walsh, Maria K. Lehtinen

### Correspondence

christopher.walsh@childrens.harvard.edu (C.A.W.), maria.lehtinen@childrens.harvard.edu (M.K.L.)

### In Brief

Smith et al. define a role for sodium channel *SCN3A* ( $\text{Na}_v1.3$ ) in the developing human cerebral cortex, as well as a cortical malformation that can result from  $\text{Na}_v1.3$  dysfunction.

### Highlights

- Mutations in *SCN3A* ( $\text{Na}_v1.3$ ) associate with perisylvian polymicrogyria
- Pathogenic *SCN3A* mutations increase persistent sodium current
- *SCN3A* is expressed during human fetal development in progenitors and neurons
- Mutated *SCN3A* alters cortical folding pattern in the ferret brain

# Sodium Channel *SCN3A* ( $\text{Na}_v1.3$ ) Regulation of Human Cerebral Cortical Folding and Oral Motor Development

Richard S. Smith,<sup>1</sup> Connor J. Kenny,<sup>1</sup> Vijay Ganesh,<sup>1</sup> Ahram Jang,<sup>2</sup> Rebeca Borges-Monroy,<sup>1</sup> Jennifer N. Partlow,<sup>1</sup> R. Sean Hill,<sup>1</sup> Taehwan Shin,<sup>1</sup> Allen Y. Chen,<sup>1</sup> Ryan N. Doan,<sup>1</sup> Anna-Kaisa Anttonen,<sup>3</sup> Jaakko Ignatius,<sup>4</sup> Livija Medne,<sup>5</sup> Carsten G. Bönnemann,<sup>5,16</sup> Jonathan L. Hecht,<sup>6</sup> Oili Salonen,<sup>7</sup> A. James Barkovich,<sup>8</sup> Annapurna Poduri,<sup>9</sup> Martina Wilke,<sup>10</sup> Marie Claire Y. de Wit,<sup>11</sup> Grazia M.S. Mancini,<sup>10</sup> Laszlo Sztriha,<sup>12</sup> Kiho Im,<sup>13</sup> Dina Amrom,<sup>14,17</sup> Eva Andermann,<sup>14</sup> Ritva Paetau,<sup>15</sup> Anna-Elina Lehesjoki,<sup>3</sup> Christopher A. Walsh,<sup>1,\*</sup> and Maria K. Lehtinen<sup>2,18,\*</sup>

<sup>1</sup>Division of Genetics and Genomics, Manton Center for Orphan Disease Research, and Howard Hughes Medical Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA

<sup>2</sup>Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA

<sup>3</sup>The Folkhälsan Institute of Genetics, 00290 Helsinki, Finland; Medical and Clinical Genetics, Neuroscience Center and Research Programs Unit, Molecular Neurology, 00014, University of Helsinki, Helsinki, Finland

<sup>4</sup>Department of Clinical Genetics, Turku University Hospital, Turku, 20521, Finland

<sup>5</sup>Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA

<sup>6</sup>Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA

<sup>7</sup>Medical Imaging Center, Radiology, University of Helsinki and Helsinki University Hospital, 00029 HUS, Helsinki, Finland

<sup>8</sup>Benioff Children's Hospital, Departments of Radiology, Pediatrics, Neurology, and Neurological Surgery, University of California San Francisco, San Francisco, CA 94117, USA

<sup>9</sup>Department of Neurology, Boston Children's Hospital and Department of Neurology, Harvard Medical School, Boston, MA 02115, USA

<sup>10</sup>Department of Clinical Genetics, Erasmus MC Rotterdam 3015CN, Netherlands

<sup>11</sup>Neurogenetics Joint Clinic in Sophia Children's Hospital, Erasmus MC Rotterdam 3015CN, Netherlands

<sup>12</sup>Department of Pediatrics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates

<sup>13</sup>Division of Newborn Medicine, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA

<sup>14</sup>Neurogenetics Unit and Epilepsy Research Group, Montreal Neurological Institute and Hospital; and the Departments of Neurology & Neurosurgery and Human Genetics, McGill University, Montreal, QC H3A 2B4, Canada

<sup>15</sup>Children's Hospital, University of Helsinki and Helsinki University Hospital, 00029 HUS, Helsinki, Finland

<sup>16</sup>Present address: Porter Neuroscience Research Center, National Institutes of Neurological Disorders and Health, Bethesda, MD 20892, USA

<sup>17</sup>Present address: Department of Neurology, Hôpital Universitaire des Enfants Reine Fabiola (HUDERF), Université Libre de Bruxelles (ULB), Brussels, Belgium; Division of Neurology, Kannerklinik, Centre Hospitalier de Luxembourg, Luxembourg, Grand Duchy of Luxembourg

<sup>18</sup>Lead Contact

\*Correspondence: [christopher.walsh@childrens.harvard.edu](mailto:christopher.walsh@childrens.harvard.edu) (C.A.W.), [maria.lehtinen@childrens.harvard.edu](mailto:maria.lehtinen@childrens.harvard.edu) (M.K.L.)

<https://doi.org/10.1016/j.neuron.2018.07.052>


## SUMMARY

Channelopathies are disorders caused by abnormal ion channel function in differentiated excitable tissues. We discovered a unique neurodevelopmental channelopathy resulting from pathogenic variants in *SCN3A*, a gene encoding the voltage-gated sodium channel  $\text{Na}_v1.3$ . Pathogenic  $\text{Na}_v1.3$  channels showed altered biophysical properties including increased persistent current. Remarkably, affected individuals showed disrupted folding (polymicrogyria) of the perisylvian cortex of the brain but did not typically exhibit epilepsy; they presented with prominent speech and oral motor dysfunction, implicating *SCN3A* in prenatal development of human cortical language areas. The development of this disorder parallels *SCN3A* expression, which we observed to be highest early in fetal cortical

development in progenitor cells of the outer sub-ventricular zone and cortical plate neurons and decreased postnatally, when *SCN1A* ( $\text{Na}_v1.1$ ) expression increased. Disrupted cerebral cortical folding and neuronal migration were recapitulated in ferrets expressing the mutant channel, underscoring the unexpected role of *SCN3A* in progenitor cells and migrating neurons.

## INTRODUCTION

Human CNS channelopathies cause a range of brain disorders (Spillane et al., 2016). However, we lack a clear understanding of ion channel functions at early stages of cerebral cortical development, particularly in progenitor cells and migrating neurons (Spillane et al., 2016). Here we describe a disease of abnormal brain development, polymicrogyria (PMG),



**Figure 1. Pathogenic Variants in SCN3A Disrupt Cerebral Cortical Formation and Oral Motor Function**

(A) MRI reconstruction of control (upper and middle panels) and age-matched affected individual B03 (lower panel). Red box outlines the PMG of perisylvian and surrounding areas.

(B) Representative MRIs of affected individuals (Families A–F) reveal cortical malformations, PMG, abnormal gyral folding patterns, and shallow sulci. White dotted circles denote affected brain regions. MRI of asymptomatic individual A09 did not reveal visible PMG. Control, unaffected 11 year old. Scale bar represents 2 cm.

(C) Family A pedigree with a dominantly inherited point mutation causing amino acid change Phe1759Tyr in SCN3A. Family B pedigree with a dominantly inherited point mutation causing amino acid change Ile1344Leu in SCN3A. Single affected individual in Family C with a *de novo* point mutation causing amino acid change Leu850Pro in SCN3A. Single affected individuals in Families D and E with a *de novo* point mutation causing amino acid change Ile875Thr in SCN3A. Single affected individual in Family F with a point mutation causing amino acid change Arg621His in SCN3A; paternal sample unavailable (NA). Square, male; circle, female; black quadrant shading, affected individual (see phenotype legend). See also Figure S1 and Table S1.

## RESULTS AND DISCUSSION


### Individuals with Pathogenic SCN3A Variants Display Aberrant Cerebral Cortical Development and Speech Deficits

Magnetic resonance imaging (MRI) and neurological evaluations of six unrelated families with oral motor and/or speech deficits demonstrate bilateral perisylvian PMG

associated with pathogenic variants in SCN3A, which encodes brain-enriched voltage-gated sodium channel (VGSC) Na<sub>v</sub>1.3.

PMG is characterized by multiple abnormally small gyri in the cerebral cortex (Kuzniecky et al., 1993). PMG in language areas can affect speech (Stutterd and Leventer, 2014); its location and extent correlate with the severity of the resulting developmental language disorder (Guerreiro et al., 2002; Jansen et al., 2005). Although case reports suggest that SCN3A variants cause early infantile epilepsy, sometimes resolving in childhood (Holland et al., 2008; Lamar et al., 2017; Vanoye et al., 2014; Zaman et al., 2018), the pathogenic SCN3A alleles we discovered manifest as a fixed perisylvian anatomical defect with prominent orofacial weakness and/or speech delay, yet epilepsy was uncommon. Our findings reveal prenatal roles for SCN3A in cortical organization and neuronal migration, especially in speech and language areas, mirroring the enriched fetal expression of SCN3A. Prenatal cortical progenitor cells and neurons do not show detectable action potentials, supporting an unexpected role for sodium channel (SCN3A) in their proliferation and migration in the developing brain.

(Families A and B; Figure 1A and 1B; Table S1), unilateral perisylvian PMG with abnormal sulcation (Families C and F), and bilateral frontoparietal PMG with microcephaly (Families D and E; Figure 1B). Families A and B are multigenerational with prominent dysarthric speech, and variable oral motor deficits and ID, clinically described previously (Guerreiro et al., 2000), compatible with autosomal dominant inheritance with incomplete penetrance (Figure 1C). Linkage and haplotype mapping, exome sequencing, and Sanger sequencing in Family A detected only one rare, predicted deleterious variant that segregated perfectly with the condition: it is heterozygous in affected individuals and obligate carriers and absent in unaffected individuals (Figures 1C and S1A–S1C). The variant occurs in SCN3A, which encodes Na<sub>v</sub>1.3 (NM\_006922.3), a VGSC alpha subunit (Na<sub>v</sub>). This channel's pore-forming structure contains four homologous domains (DI–DIV), each consisting of six membrane-spanning segments (S1–S6; Figure 2A). The SCN3A variant in Family A, c.5276T>A, p.Phe1759Tyr (F1759Y) affects a phenylalanine in the S6 segment of the fourth transmembrane domain (DIV-S6; Figures 2A and S1A), an important pore-facing subunit



**Figure 2. Pathogenic *SCN3A* Variants Alter Channel Physiology**

(A) Top: schematic of *SCN3A* alpha subunit where colored circles indicate approximate locations of mutations identified in Families A–F. Bottom: WT and pathogenic sodium channels are similarly expressed in transfected HEK293T cells.

(B) Representative voltage-clamp recordings from *SCN3A*-transfected HEK293T cells evoked by the voltage step activation protocol (5 mV increments; –100 to +50 mV). Scale bar represents 1 nA/3 ms.

(C) Left: average voltage activation curve fit with Boltzmann equation (see [STAR Methods](#)), plotted as normalized conductance against step voltage demonstrate F1759Y (red) and I875T (blue) variants produce depolarizing and hyperpolarizing shifts in voltage-dependent activation, respectively. Right upper: bar graph shows conductance of largest evoked *SCN3A* current (normalized to cell capacitance) as decreased in F1759Y (red) and I875T (blue) variants; lower: bar graph shows a positive and negative shift in  $V_{1/2}$  voltage of activation for F1759Y and I875T variants compared to WT-*SCN3A*.

(D) Upper: representative sodium currents evoked by inactivation protocol. Lower: voltage dependence of Na<sub>v</sub> current inactivation demonstrate F1759Y and I875T variants having shifted inactivation compared to WT-*SCN3A*. Boltzmann fit plotted as normalized current (channel availability) at 0 mV against the conditioning pre-pulse potential (–100 to 0 mV, See [Table S2](#)).

(E) Left: peak normalized sodium transient currents. Right: voltage step plotted versus persistent current ( $I-Na_p$ ),  $I-Na_p$  measurement collected as the mean of the last 30 ms of the voltage step and presented as percent maximal peak inward current, demonstrate increase persistent current in F1759Y and I875T variants, compared to WT.

(F) Left: representative voltage-clamp recordings, current density measurements indicated from area regions in yellow (15 ms). Right: Na<sup>+</sup> currents plotted as current density against the stepping potential demonstrate F1759Y and I875T variants differentially affect current flow compared to WT. See also [Table S2](#).

(G) Primary culture of dissociated human fetal cortical neurons generated from 19 weeks gestation (WKSG) cortical plate.

(H) Representative voltage-clamp recordings from neurons in (G) evoked by the voltage step activation protocol (20 mV increments; –80 to +40 mV) reveal sodium influx (black arrow). Scale bar represents 100 pA/1 ms.

(I) Representative current-clamp recordings from same neurons (resting  $V_m = -57$  mV) evoked by current stepping protocol (10 pA increments, 500 ms) demonstrate that fetal neurons lack action potentials, but have small voltage-activated depolarizing potentials that likely represent immature voltage-gated Na<sup>+</sup> influx (black arrow). Scale bar represents 10 mV/200 ms. Measurements presented as mean  $\pm$  SEM (t test; \* $p < 0.05$ , \*\* $p < 0.01$ ).

regulating voltage-dependent inactivation (McPhee et al., 1995; Savio-Galimberti et al., 2012). A screen of 258 individuals with PMG and variable oral motor or speech deficits for *SCN3A* variants revealed five additional families. In Family B, the variant at c.4030A>C, p.Ile1344Leu (I1344L) affects an isoleucine in the S5 segment of the third domain (DIII-S5; [Figures 1C, 2A, and S1E](#)) and was inherited by two affected siblings from their mother who had a normal MRI, suggesting that she is a non-manifesting carrier, a feature of channelopathies (Cooper et al., 2013). The siblings' maternal uncle, now deceased, reportedly never developed speech and had seizures but did not have brain imaging. The *de novo* *SCN3A* variant in Family C, c.2549T>C,

p.Leu850Pro (L850P), present in one affected child and absent from both parents, affects a leucine in the S4 voltage-sensing segment of the second domain (DII-S4; [Figures 1C, 2A, and S1F](#)). Unrelated Families D and E each have one affected child with the same *de novo* variant absent from their parents, *SCN3A* c.2624T>C, p.Ile875Thr (I875T), which is in the intracellular loop connecting the S4–S5 subunits in DII, close to the Na<sub>v</sub> voltage sensor (Savio-Galimberti et al., 2012) ([Figures 1C, 2A, and S1H](#)). The *SCN3A* variant in Family F, 1862G>A, p.Arg621His (R621H), present in one affected child and absent in maternal DNA, affects an arginine in the S6–S1 cytoplasmic linker between DI and DII ([Figures 1C and S1G](#)).

R621, L850, I875, I1344, and F1759 are highly conserved among human VGSC subtype genes (*SCN1A-SCN11A*) and invariant in other vertebrate *SCN3A* orthologs (Figures S1D–S1H). L850P, I1344L, and F1759Y are completely absent in large human genetics databases, such as the Genome Aggregation Database ([gnomAD.broadinstitute.org](http://gnomAD.broadinstitute.org)), which contains 4,877,782 exome or genome sequences for >138,000 individuals, including ~13,000 Finns. Four other I875T alleles have been reported, two individuals in large ID and developmental disability cohorts reported without further phenotypic detail (Deciphering Developmental Disorders Study, 2017; Lelieveld et al., 2016), and two individuals with PMG and severe epilepsy (one the same as reported herein) (Zaman et al., 2018), suggesting that I875T is a recurrent, severely damaging allele. *In silico* pathogenicity predictions using SIFT, MutationTaster, and PolyPhen2 suggested that R621H, L850P, I875T, I1344L, and F1759Y are all damaging and likely disease causing (STAR Methods). The mutations suggest a range of severity, from inheritance of variably penetrant perisylvian PMG and ID without epilepsy (F1759Y, I1344L) to the severely damaging recurrent I875T allele, which is *de novo* in the 5 families identified to date with widespread PMG, microcephaly, and severe seizures.

### Pathogenic *SCN3A* (Na<sub>v</sub>1.3) Variants Alter Channel Physiology

Sodium current recordings from HEK293T cells that expressed mutated *SCN3A* harboring the F1759Y or I875T alleles displayed abnormal channel properties. Using whole-cell patch recordings, we evoked transient sodium currents over a range of voltages and measured the conductance-voltage curve in transfected cells (Figure 2B). Both mutant channels exhibited abnormal peak conductance ( $I_{peak}$ ) and half-maximal voltage of activation ( $V_{1/2}$ ; Figure 2C). Compared to wild-type (WT), the F1759Y mutation produced a depolarizing shift ( $+7.8 \pm 1.6$  mV; *t* test,  $p < 0.01$ ,  $n = 28$ ), while the I875T mutation produced a hyperpolarizing shift ( $-5.4 \pm 1.7$  mV; *t* test,  $p < 0.01$ ,  $n = 17$ ; Figure 2C; see Table S2 for complete sodium current values). Na<sub>v</sub> channel availability calculated by measuring steady-state (fast) inactivation with a stepwise conditioning protocol (100 ms prepulse from  $-100$  to  $0$  mV; Figure 2D) showed a trend toward depolarizing shifts in half-maximal voltage of inactivation (F1759Y,  $5.2 \pm 1.1$  mV, *t* test,  $p = 0.24$ ,  $n = 28$ ; and I875T,  $5.5 \pm 0.6$  mV; *t* test,  $p = 0.27$ ,  $n = 17$ ; Figure 2D).

Whereas *SCN3A* channels are already distinct from *SCN1A* channels by their larger, non-inactivating persistent current (I-Na<sub>p</sub>) (Lampert et al., 2006; Sun et al., 2007), F1759Y and I875T increased this difference further. The I-Na<sub>p</sub> measured at depolarized potentials for I875T ( $+10$  to  $+50$  mV; *t* test,  $n = 17$ ,  $p < 0.05$ ), and at all potentials tested for F1759Y ( $-10$  to  $+50$  mV; *t* test,  $n = 28$ ,  $p < 0.01$ ), was greater than WT Na<sub>v</sub>1.3 controls (Figure 2E; Table S2).

Because I-Na<sub>p</sub> depolarizes cells (Stafstrom, 2007) and mutated *SCN3A* can enhance excitability (Estacion et al., 2010), we next evaluated total charge (current density) conducted by channels during a voltage step depolarization (Figure 2F). The F1759Y pathogenic variant conducted more sodium current through depolarizing potentials ( $-10$  mV to  $+25$  mV;


*t* test,  $n = 28$ ,  $p < 0.05$ ), while the I875T pathogenic variant conducted less sodium current than controls (*t* test,  $n = 17$ ,  $p < 0.01$ ; Figure 2F; Table S2). Because I-Na<sub>p</sub> is a characteristic of *SCN3A* channels and is similarly increased by both variants, it might underlie PMG associated with these variants.

Patch clamping human primary fetal cortical neurons from early-middle gestation showed small reproducible sodium currents ( $110$  pA  $\pm$   $45$  pA,  $n = 12$ ; Figure 2H), but no regenerative action potentials under the tested conditions (Figure 2I), consistent with prior reports (Moore et al., 2009). The absence of action potentials prenatally suggests that during human fetal development, *SCN3A* sodium currents may have functions beyond the classical role of action potential electrogenesis.

### *SCN3A* Expression Is Developmentally Regulated in Human Brain

Unlike *SCN1A*, *SCN3A* is robustly expressed across human cortical regions during fetal periods but downregulated after birth (Figures 3A and S3C). RNA *in situ* analyses of fetal (20 weeks gestation) human brain revealed the highest *SCN3A* expression in the cortical plate (CP), which contains immature neurons, with significant expression in the outer subventricular zone (oSVZ) and intermediate zone (IZ), but low expression in the ventricular zone (VZ; Figures 3C, 3E, and S3B). Consistent with this pattern, single-cell RNA sequencing (scRNA-seq) data at 16–18 weeks gestation (Pollen et al., 2015) showed *SCN3A* enrichment in intermediate progenitors and neurons (Figures 3B and S3A), and *in situ* analysis showed expression in outer radial glia (oRG; Figures S3B) as well, a progenitor cell type present in developing gyrencephalic brains (non-human primates and humans) but rare or absent in mice (Florio and Huttner, 2014). oRG cells, but not ventricular RG cells, display small sodium currents (Hansen et al., 2010), suggesting that *SCN3A* underlies sodium conductance in these cortical progenitors, which are key to gyrification. Adult human cortex (38 years old) showed very low *SCN3A* expression across all cortical layers (Figures 3D, 3F, and S3C).

*SCN3A* expression differs sharply from that of other VGSCs, including *SCN1A*, which was lower during gestation and upregulated postnatally (Figures 3A and S3C). Low *SCN1A* expression during gestation was confirmed across all fetal cortical cell types by scRNA-seq (two-part Wilcoxon test,  $p < 0.005$ ; Figure 3B). Notably, postnatal upregulation of *SCN1A* correlates with the age of onset of epilepsy associated with *SCN1A* variants (Spillane et al., 2016). Clinical reports have associated other *SCN3A* variants with infantile epilepsy that resolves with age (Vanoye et al., 2014), perhaps because fetal *SCN3A* expression later decreases. Mice also display post-natal *Scn3a* downregulation (Beckh et al., 1989; Gordon et al., 1987), and mice with loss-of-function (LOF) *Scn3a* mutations do not display spontaneous seizures (Lamar et al., 2017). Thus, different expression patterns between *SCN1A* and *SCN3A* may relate to the ages of onset and severity of VGSC channelopathies, possibly explaining the limited adult epilepsy observed in individuals with *SCN3A* pathogenic variants in this study (Families A, B, C, and E), and the absence of brain malformations seen with *SCN1A* mutations (Spillane et al., 2016).



**Figure 3. *SCN3A* Expression Is Developmentally Regulated in Human Brain**

(A) *SCN3A* transcripts are enriched during fetal gestational weeks (WKS) and decrease postnatally. *SCN1A* ( $Na_v1.1$ ) expression starts lower and increases postnatally. Raw data analyzed from Allen Brain Atlas, presented as  $\log_2$  RPKM (reads per kilobase per million) values. See also Figure S3C. (B) Single-cell RNA-seq dataset generated from 16–18 WKS fetal cortex (Pollen et al., 2015) shows higher *SCN3A* versus *SCN1A* expression in radial glial cells (RGCs), intermediate progenitor cells (IPC), and neurons (RGCs:  $p < 0.005$ ; IPCs:  $p < 0.001$ ; neurons:  $p < 0.001$ ). Graph depicts two-part Wilcoxon test; \*\* $p < 0.01$ , \*\*\* $p < 0.001$  with Bonferroni adjusted alpha level of 0.017 (0.05/3). See also Figure S3A.

(C) *SCN3A* mRNA *in situ* hybridization at 20 WKS shows higher expression in the cortical plate (CP) and lower expression in the subventricular zone (SVZ).

(D) *SCN3A* mRNA *in situ* hybridization in adult cortex. *NeuN* (*RBFOX3*) mRNA *in situ* hybridization reveals architecture and neurons in tissue section (38 years old; scale bar represents 1 cm).

(E) Chromogenic mRNA *in situ* hybridization (i) and corresponding fluorescence imaging (ii) of 20 WKS brain. Cell-type-specific markers for intermediate progenitors (TBR2) and neural progenitors (Vimentin, VIM) show *SCN3A* transcripts in SVZ/VZ. Scale bar on the left represents 500  $\mu$ m; scale bar on the right represents 25  $\mu$ m. See also Figure S3A.


(F) mRNA *in situ* for *SCN3A* (i) and *NeuN* (ii) with fluorescence imaging (iii) of adult cortex (38 years old, Brodmann area 27). Scale bar represents 500  $\mu$ m. VZ, ventricular zone; IMZ, intermediate zone; SP, subplate; WM, white matter; Roman numerals (I–VI) correspond to approximate cortical layers. See also Figure S3.

### Overexpression of *SCN3A* in Human Cortical Neurons Stimulates Neurite Branching but Is Impaired by I875T and F1759Y Mutants

Expression of *SCN3A* in cultured human fetal neurons produced a modest increase in neurite branching without an overall increase in neurite length, and this branching effect was attenuated by both I875T and F1759Y mutants (Figure S2). Fetal neurons overexpressing the I875T mutant displayed modestly shorter neurites overall, similar to neuropathy-associated  $Na_v1.7$  mutations that disrupts neurites (Estacion et al., 2015), whereas *SCN3A*-F1759Y showed no differences compared to controls (Figure S2C). Overexpression of the  $\beta$ - $Na_v$  subunit, which affects persistent current (Aman et al., 2009), increased neurite length (Figure S2C), consistent with previous reports in rodent cortical neurons (Brackenbury et al., 2008). These results further support the possibility that *SCN3A* regulates neuronal development through action potential-independent mechanisms and that the disease-associated mutations impact these processes.

### Altered *SCN3A* Expression Disrupts Ferret Cerebral Cortical Development

*SCN3A*-F1759Y mutation disrupted cortical gyral formation *in vivo* in the developing ferret cerebral cortex (Figure 4). Unlike rodents, ferret brains possess a stereotyped pattern of gyri and sulci, a human-like molecular diversity of progenitor cells, and a developmental timeline that permits transient gene overexpression in embryos via *in utero* electroporation (IUE) (Johnson et al., 2015; Kawasaki et al., 2012). Following IUE delivery of F1759Y or WT *SCN3A* at embryonic day 33 (E33), we analyzed ferret brains at: (1) birth (postnatal day 0 [P0]), coincident with mid-cortico-genesis (cortical layers are still forming and cortex largely smooth), and (2) P33, when gyri and sulci are more fully formed. At P0, F1759Y overexpression severely disrupted neuronal migration: Tuj1-positive neurons were displaced near the VZ and SVZ instead of arriving at their age-appropriate cortical laminae (Figure 4C). At P33 (Figure 4E), F1759Y-transfected embryos developed atypical gyrfication patterns, including the formation of additional sulci and gyri (5 of 5 ferrets



**Figure 4. Expression of Mutant *SCN3A* Disrupts Neuronal Migration and Ferret Cerebral Cortical Gyrfication**

(A) Schematic of human and ferret development and study design.

(B and C) Cerebral cortex of kits (P0) following an IUE at E33 with mCherry together with *SCN3A*-WT (B) or -F1759Y (C); tiled confocal images; scale bar represents 25  $\mu$ m. Colocalization of mCherry-positive cells in the VZ/SVZ with cell-type-specific markers: progenitor (Ki67, TBR2), glial-astrocyte (GFAP), and neuronal (TUJ1) show mCherry expression in neurons.

(D) Distribution pattern across cortex (bins 1–5) of mCherry-positive cells in (A) reveals *SCN3A* alters neuronal migration (t test; \*p < 0.05, \*\*p < 0.01). See also Figure S4F.

(E) Upper: schematics of study design and stereotyped ferret gyri/sulci at P33. Lower: P30 ferret brain expressing electroporated *SCN3A*-F1759Y resulting in atypical gyrfication pattern.

(F) MRI images of P33 brain expressing *SCN3A*-F1759Y; scale bar represents 5 mm. Right: arrow denotes clusters of gray matter heterotopia.

(legend continued on next page)

examined; [Figures 4E and S4C](#)). At both time points (P0 and P33), the overexpression of *SCN3A*-WT had modest effects: neuronal migration was slightly altered at P0 ([Figure 4B](#)), perhaps resulting from enhanced sodium entry, and the gyral phenotype was modestly affected at P33 (2 of 6 ferrets examined; [Figures 4H and S4C](#)). Similar injections of a control vector did not alter the gyrification pattern (0 of 5 ferrets examined; [Figures 4J and S4C](#)).

Finally, reconstruction of MRI images of adult ferret cortices revealed formation of cortical gray matter heterotopia in *SCN3A*-F1759Y-expressing brains ([Figure 4F](#)), but not in *SCN3A*-WT or empty vector controls ([Figures 4I and 4K](#)). Heterotopia consisted of displaced F1759Y mCherry-positive cells ([Figure 4G](#)), intermixed with mCherry-negative and SATB2-positive cells, an upper layer cortical marker ([Figure S4E](#)), suggesting that some of the migratory defect involved WT cells disrupted non-cell-autonomously, perhaps by loss or damage to radial glia that do not normally express *SCN3A*. Evaluation of SATB2-positive cells at P15 also confirmed robust displacement of these cells in electroporated regions ([Figure S4D](#)). MRI analyses of *SCN3A*-WT and empty vector-expressing controls did not show displaced cells or heterotopia ([Figures 4I and 4K](#)). Together, these findings further support the model that *SCN3A* gene dosage, in addition to acquired pathological mutations, alters early cerebral cortical development, with sodium channel dysregulation leading to both cell-autonomous effects in neurons and potential effects on other cell types as well.

Prenatal *SCN3A* may not always involve classic action potential upstroke generation. Human oRG and astrocytes show functional sodium channels, with small and prolonged conductances, but no action potentials ([Black et al., 1995](#); [Hansen et al., 2010](#); [Sontheimer and Waxman, 1993](#)). Here, immature cortical neurons isolated when the sylvian fissure is developing did not show regenerative action potentials *in vitro*, but *SCN3A* may contribute Na<sup>+</sup> conductances that modulate other voltage-dependent processes and downstream pathways, e.g., calcium signaling. In glia and neurons, changes to sodium flux can reverse Na<sup>+</sup>/Ca<sup>2+</sup> exchangers, triggering calcium waves and neurite degeneration, as well as activating Rac1 and ERK1/2 ([Estacion et al., 2015](#); [Pappalardo et al., 2014](#); [Persson et al., 2014](#)). Additional noncanonical roles of VGSCs in nonexcitable cells that might be affected include the release of bioactive molecules, regulation of Na<sup>+</sup>/K<sup>+</sup>-ATPase activity and cell motility, or a role in intracellular membranes to modulate phagocytosis ([Black and Waxman, 2013](#)). Fetal *SCN3A* mutations may activate different mechanisms than mutations in other VGSCs, like *SCN1A*, that are expressed postnatally, when both GOF and LOF are likely to modify excitability, altering circuit function ([Blanchard et al., 2015](#); [Escayg and Goldin, 2010](#)), and *SCN2A*, where LOF (but not GOF) is reported in individuals with autism spectrum disorders without epilepsy ([Ben-Shalom et al., 2017](#)). As channels that affect membrane potential are important for cortical development ([Ackman and Crair, 2014](#); [LoTurco et al., 1995](#);

[Rash et al., 2016](#)), and modifications to membrane potential in progenitor cells can disrupt cortical lamination in mice ([Hurni et al., 2017](#)), regulation of ion flux may represent a conserved mechanism governing development of several cell types.

To date, genetic evidence connecting cortical malformations with oral motor and developmental language disorders is limited. [Guerreiro et al. \(2002\)](#) and [Jansen et al. \(2005\)](#) demonstrated the presence of a developmental language delay in individuals with bilateral perisylvian PMG, and the high prevalence of PMG in persons with developmental language delay. Both studies correlated the location and extent of the cortical malformation with the type and severity of developmental language delay. The perisylvian region contains key language areas that can be affected by PMG ([Stutterd and Leventer, 2014](#)). Notably, infantile epilepsy cases with *SCN3A* variants not showing PMG may display variable abnormalities in oral motor and speech development ([Lamar et al., 2017](#); [Vanoye et al., 2014](#)). *SCN3A* deficits also overlap with features of syndromes caused by mutations in the N-methyl-D-aspartate receptor subunit *GRIN2A* and the transcription factor *FOXP2* ([Morgan et al., 1993](#); [Turner et al., 2015](#)) as well as the inherited “Worster-Drought” syndrome ([Clark et al., 2000](#)), which resembles several of our *SCN3A* families. Understanding the early function of these genes will illuminate development of the Sylvian fissure and its adjacent perisylvian language and oral motor areas.

## STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- [KEY RESOURCES TABLE](#)
- [CONTACT FOR REAGENT AND RESOURCE SHARING](#)
- [EXPERIMENTAL MODEL AND SUBJECT DETAILS](#)
  - Human subjects and samples
  - Phenotypic assessment
  - Clinical description of families
- [METHODS DETAILS](#)
  - Human genetics
  - Identification and segregation of alleles
  - Electrophysiology
  - Human tissue brain preparation and mRNA *in situ* hybridization
  - Ferret *in utero* electroporation
  - Ferret tissue preparation and immunohistochemistry
  - Membrane protein extraction and immunoblotting
- [QUANTIFICATION AND STATISTICAL ANALYSIS](#)
  - Quantitative MRI analysis
  - Human gene expression analysis
  - Analysis of single cell RNA-seq data
  - Primary neuronal cultures and neurite analysis
  - Ferret brain magnetic resonance imaging
- [DATA AND SOFTWARE AVAILABILITY](#)

(G) Upper: mCherry-positive (red) and Nissl-positive (green) cells in brain sections from (F); scale bar represents 2 mm. Inset: higher-magnification image suggesting a non-cell-autonomous effect of *SCN3A* activation (right panel scale bar represents 200 μm). Lower: mCherry-positive cells analyzed as in (C).

(H–K) Examples of brains expressing WT *SCN3A* (H and I) and mCherry vector (J and K), show stereotyped brain development. Scale bar represents 5 mm. See also [Figure S4](#).



## SUPPLEMENTAL INFORMATION

Supplemental Information includes four figures and two tables and can be found with this article online at <https://doi.org/10.1016/j.neuron.2018.07.052>.

## ACKNOWLEDGMENTS

We are grateful to the families reported here. We thank F. Andermann, B. Bean, and members of the Clapham, Lehtinen, and Walsh labs for helpful discussions; B. Bean and D. Clapham for sharing electrophysiology equipment, M. Marcotrigiano, Y. Wu, and the Boston Children's Hospital Small Animal Imaging Lab for MRI, E. Pollack and A. Nedder, and the Boston Children's Hospital large animal facility, D. Gleason, J. Rodriguez, A. Malesz, R. Hu, for technical help, A. Pollen for sharing single cell sequencing data, J. Kearney for the WT SCN3A plasmid, D. Nguyen and L. Al-Gazali for assistance with clinical data. This work was supported by NIH 1F32NS100033801 (R.S.S.); the Erasmus MC Mrace project #104673 (G.M.S.M.); the Finnish Medical Society, Arvo and Lea Ylppö Foundation, and Finnish governmental subsidiaries TLK0278 (R.P.) and TRTR019 (O.S.); The Folkhälsan Research Foundation (A.-E.L.); Paul G. Allen Frontiers Program, and NIH R01NS032457 and R01NS035129 (C.A.W.), the New York Stem Cell Foundation (M.K.L.), and BCH IDDRC 1U54HD090255. C.A.W. is an Investigator of the Howard Hughes Medical Institute. M.K.L. is a New York Stem Cell Foundation – Robertson Investigator.

## AUTHOR CONTRIBUTIONS

D.A., E.A., A.J.B., C.G.B., J.L.H., J.I., A.-E.L., L.M., G.M.S.M., R.P., A.P., O.S., L.S., M.W., M.C.d.Y.W., and C.A.W. collected and evaluated clinical data; A.-K.A., A.Y.C., R.N.D., V.G., R.S.H., K.I., C.J.K., A.-E.L., M.K.L., A.P., T.S., R.S.S., and M.W. analyzed human genetics data; D.A., E.A., J.I., L.M., J.N.P., and R.P. coordinated clinical data, A.J., C.J.K., M.K.L., R.B.-M., and R.S.S. performed and analyzed cell-based experiments; R.S.S., M.K.L., and C.A.W. wrote the manuscript, and all co-authors edited it.

## DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: December 28, 2017

Revised: June 5, 2018

Accepted: July 30, 2018

Published: August 23, 2018

## REFERENCES

- Ackman, J.B., and Crair, M.C. (2014). Role of emergent neural activity in visual map development. *Curr. Opin. Neurobiol.* *24*, 166–175.
- Aman, T.K., Grieco-Calub, T.M., Chen, C., Rusconi, R., Slat, E.A., Isom, L.L., and Raman, I.M. (2009). Regulation of persistent Na current by interactions between beta subunits of voltage-gated Na channels. *J. Neurosci.* *29*, 2027–2042.
- Beckh, S., Noda, M., Lübbert, H., and Numa, S. (1989). Differential regulation of three sodium channel messenger RNAs in the rat central nervous system during development. *EMBO J.* *8*, 3611–3616.
- Ben-Shalom, R., Keeshen, C.M., Berrios, K.N., An, J.Y., Sanders, S.J., and Bender, K.J. (2017). Opposing Effects on Nav1.2 Function Underlie Differences Between SCN2A Variants Observed in Individuals With Autism Spectrum Disorder or Infantile Seizures. *Biol. Psychiatry* *82*, 224–232.
- Black, J.A., and Waxman, S.G. (2013). Noncanonical roles of voltage-gated sodium channels. *Neuron* *80*, 280–291.
- Black, J.A., Westenbroek, R., Minturn, J.E., Ransom, B.R., Catterall, W.A., and Waxman, S.G. (1995). Isoform-specific expression of sodium channels in astrocytes in vitro: immunocytochemical observations. *Glia* *14*, 133–144.
- Blanchard, M.G., Willemsen, M.H., Walker, J.B., Dib-Hajj, S.D., Waxman, S.G., Jongmans, M.C., Kleefstra, T., van de Warrenburg, B.P., Praamstra, P., Nicolai, J., et al. (2015). De novo gain-of-function and loss-of-function mutations of SCN8A in patients with intellectual disabilities and epilepsy. *J. Med. Genet.* *52*, 330–337.
- Brackenbury, W.J., Davis, T.H., Chen, C., Slat, E.A., Detrow, M.J., Dickendesh, T.L., Ranscht, B., and Isom, L.L. (2008). Voltage-gated Na<sup>+</sup> channel beta1 subunit-mediated neurite outgrowth requires Fyn kinase and contributes to postnatal CNS development in vivo. *J. Neurosci.* *28*, 3246–3256.
- Clark, M., Carr, L., Reilly, S., and Neville, B.G. (2000). Worster-Drought syndrome, a mild tetraplegic perisylvian cerebral palsy. Review of 47 cases. *Brain* *123*, 2160–2170.
- Cooper, D.N., Krawczak, M., Polychronakos, C., Tyler-Smith, C., and Kehrer-Sawatzki, H. (2013). Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. *Hum. Genet.* *132*, 1077–1130.
- Deciphering Developmental Disorders Study (2017). Prevalence and architecture of de novo mutations in developmental disorders. *Nature* *542*, 433–438.
- Escayg, A., and Goldin, A.L. (2010). Sodium channel SCN1A and epilepsy: mutations and mechanisms. *Epilepsia* *51*, 1650–1658.
- Estacion, M., Gasser, A., Dib-Hajj, S.D., and Waxman, S.G. (2010). A sodium channel mutation linked to epilepsy increases ramp and persistent current of Nav1.3 and induces hyperexcitability in hippocampal neurons. *Exp. Neurol.* *224*, 362–368.
- Estacion, M., Vohra, B.P.S., Liu, S., Hoeijmakers, J., Faber, C.G., Merckies, I.S.J., Lauria, G., Black, J.A., and Waxman, S.G. (2015). Ca<sup>2+</sup> toxicity due to reverse Na<sup>+</sup>/Ca<sup>2+</sup> exchange contributes to degeneration of neurites of DRG neurons induced by a neuropathy-associated Nav1.7 mutation. *J. Neurophysiol.* *114*, 1554–1564.
- Florio, M., and Huttner, W.B. (2014). Neural progenitors, neurogenesis and the evolution of the neocortex. *Development* *141*, 2182–2194.
- Gordon, D., Merrick, D., Auld, V., Dunn, R., Goldin, A.L., Davidson, N., and Catterall, W.A. (1987). Tissue-specific expression of the RI and RII sodium channel subtypes. *Proc. Natl. Acad. Sci. USA* *84*, 8682–8686.
- Guerreiro, M.M., Andermann, E., Guerrini, R., Dobyns, W.B., Kuzniecky, R., Silver, K., Van Bogaert, P., Gillain, C., David, P., Ambrosetto, G., et al. (2000). Familial perisylvian polymicrogyria: a new familial syndrome of cortical maldevelopment. *Ann. Neurol.* *48*, 39–48.
- Guerreiro, M.M., Hage, S.R.V., Guimaraes, C.A., Abramides, D.V., Fernandes, W., Pacheco, P.S., Piovesana, A.M.S.G., Montenegro, M.A., and Cendes, F. (2002). Developmental language disorder associated with polymicrogyria. *Neurology* *59*, 245–250.
- Guerrini, R., Barkovich, A.J., Sztriha, L., and Dobyns, W.B. (2000). Bilateral frontal polymicrogyria A newly recognized brain malformation syndrome. *Neurology* *54*, 909–913.
- Hansen, D.V., Lui, J.H., Parker, P.R.L., and Kriegstein, A.R. (2010). Neurogenic radial glia in the outer subventricular zone of human neocortex. *Nature* *464*, 554–561.
- Holland, K.D., Kearney, J.A., Glauser, T.A., Buck, G., Keddache, M., Blankston, J.R., Glauser, I.W., Kass, R.S., and Meisler, M.H. (2008). Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy. *Neurosci. Lett.* *433*, 65–70.
- Hurni, N., Kolodziejczak, M., Tomasello, U., Badia, J., Jacobshagen, M., Prados, J., and Dayer, A. (2017). Transient Cell-intrinsic Activity Regulates the Migration and Laminar Positioning of Cortical Projection Neurons. *Cereb. Cortex* *27*, 3052–3063.
- Jansen, A.C., Leonard, G., Bastos, A.C., Esposito-Festen, J.E., Tampieri, D., Watkins, K., Andermann, F., and Andermann, E. (2005). Cognitive functioning in bilateral perisylvian polymicrogyria (BPP): clinical and radiological correlations. *Epilepsy Behav.* *6*, 393–404.
- Johnson, M.B., Wang, P.P., Atabay, K.D., Murphy, E.A., Doan, R.N., Hecht, J.L., and Walsh, C.A. (2015). Single-cell analysis reveals transcriptional heterogeneity of neural progenitors in human cortex. *Nat. Neurosci.* *18*, 637–646.
- Jones, A., Overly, C.C., and Sunkin, S.M. (2009). The Allen Brain Atlas: 5 years and beyond. *Nat. Rev. Neurosci.* *10*, 821–828.

- Kawasaki, H., Iwai, L., and Tanno, K. (2012). Rapid and efficient genetic manipulation of gyrencephalic carnivores using in utero electroporation. *Mol. Brain* 5, 24.
- Kuzniecky, R., Andermann, F., and Guerrini, R. (1993). Congenital bilateral perisylvian syndrome: study of 31 patients. The CBPS Multicenter Collaborative Study. *Lancet* 341, 608–612.
- Lamar, T., Vanoye, C.G., Calhoun, J., Wong, J.C., Dutton, S.B.B., Jorge, B.S., Velinov, M., Escayg, A., and Kearney, J.A. (2017). SCN3A deficiency associated with increased seizure susceptibility. *Neurobiol. Dis.* 102, 38–48.
- Lampert, A., Hains, B.C., and Waxman, S.G. (2006). Upregulation of persistent and ramp sodium current in dorsal horn neurons after spinal cord injury. *Exp. Brain Res.* 174, 660–666.
- Lelieveld, S.H., Reijnders, M.R., Pfundt, R., Yntema, H.G., Kamsteeg, E.J., de Vries, P., de Vries, B.B., Willemsen, M.H., Kleefstra, T., Löhner, K., et al. (2016). Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability. *Nat. Neurosci.* 19, 1194–1196.
- LoTurco, J.J., Owens, D.F., Heath, M.J., Davis, M.B., and Kriegstein, A.R. (1995). GABA and glutamate depolarize cortical progenitor cells and inhibit DNA synthesis. *Neuron* 15, 1287–1298.
- McPhee, J.C., Ragsdale, D.S., Scheuer, T., and Catterall, W.A. (1995). A critical role for transmembrane segment IVS6 of the sodium channel  $\alpha$  subunit in fast inactivation. *J. Biol. Chem.* 270, 12025–12034.
- Moore, A.R., Filipovic, R., Mo, Z., Rasband, M.N., Zecevic, N., and Antic, S.D. (2009). Electrical excitability of early neurons in the human cerebral cortex during the second trimester of gestation. *Cereb. Cortex* 19, 1795–1805.
- Morgan, A., Fisher, S.E., Scheffer, I., Hildebrand, and M. (1993). FOXP2-Related Speech and Language Disorders. In *GeneReviews*, M.P. Adam, H.H. Ardinger, R.A. Pagon, S.E. Wallace, L.J.H. Bean, K. Stephens, and A. Amemiya, eds. (University of Washington), pp. 1993–2018.
- Pappalardo, L.W., Samad, O.A., Black, J.A., and Waxman, S.G. (2014). Voltage-gated sodium channel Nav 1.5 contributes to astrogliosis in an in vitro model of glial injury via reverse Na<sup>+</sup>/Ca<sup>2+</sup> exchange. *Glia* 62, 1162–1175.
- Persson, A.-K., Estacion, M., Ahn, H., Liu, S., Stamboulian-Platel, S., Waxman, S.G., and Black, J.A. (2014). Contribution of sodium channels to lamellipodial protrusion and Rac1 and ERK1/2 activation in ATP-stimulated microglia. *Glia* 62, 2080–2095.
- Pollen, A.A., Nowakowski, T.J., Chen, J., Retallack, H., Sandoval-Espinosa, C., Nicholas, C.R., Shuga, J., Liu, S.J., Oldham, M.C., Diaz, A., et al. (2015). Molecular identity of human outer radial glia during cortical development. *Cell* 163, 55–67.
- Rash, B.G., Ackman, J.B., and Rakic, P. (2016). Bidirectional radial Ca<sup>2+</sup> activity regulates neurogenesis and migration during early cortical column formation. *Sci. Adv.* 2, e1501733.
- Savio-Galimberti, E., Gollob, M.H., and Darbar, D. (2012). Voltage-gated sodium channels: biophysics, pharmacology, and related channelopathies. *Front. Pharmacol.* 3, 124.
- Sontheimer, H., and Waxman, S.G. (1993). Expression of voltage-activated ion channels by astrocytes and oligodendrocytes in the hippocampal slice. *J. Neurophysiol.* 70, 1863–1873.
- Spillane, J., Kullmann, D.M., and Hanna, M.G. (2016). Genetic neurological channelopathies: molecular genetics and clinical phenotypes. *J. Neurol. Neurosurg. Psychiatry* 87, 37–48.
- Stafstrom, C.E. (2007). Persistent sodium current and its role in epilepsy. *Epilepsy Curr.* 7, 15–22.
- Stutterd, C.A., and Leventer, R.J. (2014). Polymicrogyria: a common and heterogeneous malformation of cortical development. *Am. J. Med. Genet. C. Semin. Med. Genet.* 166C, 227–239.
- Sun, G.-C., Werkman, T.R., Battefeld, A., Clare, J.J., and Wadman, W.J. (2007). Carbamazepine and topiramate modulation of transient and persistent sodium currents studied in HEK293 cells expressing the Na(v)1.3 alpha-subunit. *Epilepsia* 48, 774–782.
- Turner, S.J., Mayes, A.K., Verhoeven, A., Mandelstam, S.A., Morgan, A.T., and Scheffer, I.E. (2015). GRIN2A: an aptly named gene for speech dysfunction. *Neurology* 84, 586–593.
- Vanoye, C.G., Gurnett, C.A., Holland, K.D., George, A.L., Jr., and Kearney, J.A. (2014). Novel SCN3A variants associated with focal epilepsy in children. *Neurobiol. Dis.* 62, 313–322.
- Zaman, T., Helbig, I., Božović, I.B., DeBrosse, S.D., Bergqvist, A.C., Wallis, K., Medne, L., Maver, A., Peterlin, B., Helbig, K.L., et al. (2018). Mutations in SCN3A cause early infantile epileptic encephalopathy. *Ann. Neurol.* 83, 703–717.

## STAR★METHODS

### KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Mouse anti-Vimentin (IHC)	MBL International Corporation	Cat# D076-3; RRID:AB_592963
Rabbit anti-Ki67	Abcam	Cat# ab15580; RRID:AB_443209
Chicken anti-GFAP	Abcam	Cat# ab4674; RRID:AB_304558
Mouse anti-TUJ1 (beta-III tubulin)	Abcam	Cat# ab7751; RRID:AB_306045
Rabbit anti-RFP	Rockland Antibodies & Assays	Cat# 600-901-379S; RRID:AB_10703148
Rabbit anti-SATB2	Bethyl Laboratories Inc	Cat# A301-864A; RRID:AB_1309783
Rabbit anti-Pan Na Channel (clone D219C)	Cell Signaling Tech	Cat# 14380S; RRID:AB_2737019
Mouse anti-ATP1A1 (clone 464.6)	ThermoFisher	Cat# MA1-16731; RRID:AB_2060993
Chicken anti-GFP	Abcam	Cat# ab13970; RRID:AB_300798
Alexa Fluor 488, 594, 650 goat anti-Mouse/ Rabbit/Chicken	Invitrogen	Cat# 11001-10; RRID:AB_2633275
<b>Bacterial and Virus Strains</b>		
pIR-CMV-SCN3A-SV40	Jennifer Kearny	<a href="#">Vanoye et al., 2014</a>
pCMV-eGFP-IRES-β1-SV40	Jennifer Kearny	<a href="#">Vanoye et al., 2014</a>
pCMV-eGFP-IRES-β2-SV40	Jennifer Kearny	<a href="#">Vanoye et al., 2014</a>
pCMV-mCherry	Walsh Lab	N/A
<b>Biological Samples</b>		
Human Fetal Tissue	This paper	N/A
Healthy Human Adult Brain Tissue	NIH BioBank	<a href="https://neurobiobank.nih.gov">https://neurobiobank.nih.gov</a>
<b>Chemicals, Peptides, and Recombinant Proteins</b>		
Dulbecco's modified Eagle's medium	ThermoFisher	Cat# 21331-020
BrainPhys Media	Stem Cell Tech	Cat# 05790
10% fetal bovine serum	ThermoFisher	Cat# 10437010
Lipofectamine 3000 reagent	ThermoFisher	Cat# L3000001
4–15% SDS-polyacrylamide gels	Bio-Rad	Cat# 4561086
PVDF membrane	GE Healthcare Life Science	Cat# 10600058
poly-ornithine	Sigma Aldrich	Cat# P4957-50ML
Laminin	ThermoFisher	Cat# 23017015
Neurobasal	ThermoFisher	Cat# 21103049
N2	ThermoFisher	Cat# 17502048
B27	ThermoFisher	Cat# 17504044
FGF	ThermoFisher	Cat# PHG0264
EGF	ThermoFisher	Cat# PHG0314
Fomblin oil 16/6	Cole-Parmer	Cat# UX-79751-71
<b>Critical Commercial Assays</b>		
RNAscope Multiplex <i>In situ</i> kit	Advanced Cell Diagnostic	Cat# 323110
Mem-PER Plus Membrane Protein Extraction Kit for Mammalian Cells	ThermoFisher	Cat# 89842
<b>Deposited Data</b>		
scRNA seq	Alex Pollen; <a href="#">Pollen et al., 2015</a>	dbGaP: phs000989.v1.p1
Bulk Cortical Transcriptome	Allen Brain Atlas: BrainSpan project data	<a href="https://www.developinghumanbrain.org">https://www.developinghumanbrain.org</a>
Sequencing data	This Study	GEO: phs000492.v3.p1

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Experimental Models: Cell Lines		
HEK293T	ATCC	Cat# CRL-3216; RRID:CVCL_0063
Human Primary Neurons	This paper	N/A
STBL3 line	ThermoFisher	Cat# C737303
Experimental Models: Organisms/Strains		
Ferrets ( <i>Mustela putorius furo</i> )	Marshall Bioresources	N/A
Oligonucleotides		
<i>Vimentin (in situ)</i>	Advanced Cell Diagnostics	Cat# 479411
<i>SCN3A (in situ)</i>	Advanced Cell Diagnostics	Cat# 460121
<i>GFAP (in situ)</i>	Advanced Cell Diagnostics	Cat# 311801
<i>RBFOX (in situ)</i>	Advanced Cell Diagnostics	Cat# 415591
<i>EOMES (in situ)</i>	Advanced Cell Diagnostics	Cat# 429691
Software and Algorithms		
Fiji/ImageJ	Rasband, W.S., ImageJ, U.S. National Institutes of Health, Maryland	<a href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</a>
Zen Black/Blue	Zeiss, <a href="http://zeiss.com">zeiss.com</a>	N/A
Free surfer	Mass. General Hospital,	<a href="http://surfer.nmr.mgh.harvard.edu">http://surfer.nmr.mgh.harvard.edu</a>
Osyrinx	Pixmeo, <a href="http://www.osirixviewer.com">http://www.osirixviewer.com</a>	Version: OsiriX Lite
pClamp	Molecular Devices, <a href="https://www.moleculardevices.com/systems/conventional-patch-clamp/pclamp-10-software">https://www.moleculardevices.com/systems/conventional-patch-clamp/pclamp-10-software</a>	Version: pclamp10
Igor Pro 7	Wave Metrics	<a href="https://www.wavemetrics.com/">https://www.wavemetrics.com/</a>
Adobe Illustrator CC 2017	Adobe	<a href="https://www.adobe.com/products/illustrator.html">https://www.adobe.com/products/illustrator.html</a> ; <a href="https://www.adobe.com/products/illustrator.html">https://www.adobe.com/products/illustrator.html</a>
Other		
SuperFrost Plus slides	Fisher Scientific	Cat# 22-037-246
ImmEdge Pen	Vector Labs	Cat# H-4000
Zeiss AXIO observer	Zeiss	N/A
Zeiss LSM700 confocal microscope	Zeiss	N/A
Leica Research Cryostat	Leica	Model # CM3050 S
Axopatch-200B amplifier	Axon Instrument	N/A
Hamilton TLC Gastight Syringes: RN Termination	Hamilton Company	Cat# 14-815-11
NeuroTrac 435/455 Blue Fluorescent Nissl Stain	ThermoFisher	Cat# N21479
4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI)	Sigma-Aldrich	Cat# D9542

**CONTACT FOR REAGENT AND RESOURCE SHARING**

Further information and requests for resources and reagents should be directed to and will be fulfilled by Lead Contact, Maria K. Lehtinen ([maria.lehtinen@childrens.harvard.edu](mailto:maria.lehtinen@childrens.harvard.edu)).

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

**Human subjects and samples**

Research performed on samples of human origin was conducted according to protocols approved by the institutional review boards of Boston Children's Hospital, Beth Israel Deaconess Medical Center, Montreal Neurological Hospital and Institute, Erasmus MC UMC Rotterdam, and by The Children's Hospital of University of Helsinki. Subjects were identified and evaluated in a clinical setting, and biological samples collected after obtaining written informed consent. Fetal brain tissue was received after release from clinical

pathology, with a maximum post-mortem interval of 4 h. Cases with known anomalies were excluded. Male and female brain tissue was collected from 17–20 gestation weeks. Tissue was transported in HBSS medium on ice to the laboratory for research processing.

### Phenotypic assessment

All affected individuals and clinical data were examined by neurologists and radiologists, and polymicrogyria was diagnosed using criteria described previously (Guerreiro et al., 2000). Detailed clinical information on affected individuals in Family A was collected over a 20-year period, summarized in Table S1. The affected individuals of Families B–F were evaluated by neurologists over many years and detailed clinical and radiographic evaluations are described in supplemental results text.

### Clinical description of families

Family A, a multigenerational Finnish family, is the largest family with bilateral perisylvian polymicrogyria (PMG) reported to date (Guerreiro et al., 2000), having four pairs of affected siblings with variable penetrance and expression of PMG and oral motor dysfunction (dysarthric speech and deficient tongue movement) (Figures 1B and 1C; Table S1). With the exception of a single rolandic seizure in one individual (A12), neurological evaluation of the affected individuals performed throughout life confirmed the absence of epilepsy in Family A. Two affected individuals (A11 and A12) showed slightly subnormal language comprehension and intellectual ability, and these features ranged from borderline normal to subnormal in others (Figure 1C; Table S1).

Family B is a multigenerational French Canadian family with bilateral perisylvian PMG and oral motor dyspraxia (Figures 1B and 1C). As previously described, the two affected siblings (B02 and B03) had delayed speech development and a history of choking in infancy, and have dysarthria, drooling and significant restriction of tongue movements. Additionally, they were both noted to have difficulty whistling and blowing, abnormal brisk jaw jerk, increased reflexes, absent gag reflex and automatic involuntary dissociation of facial movements (Guerreiro et al., 2000). Upon reevaluation at 43 years of age, B03 had macrocephaly with a head circumference of 57 cm (99<sup>th</sup> percentile, 2.4 standard deviations), her height was 163 cm (48<sup>th</sup> percentile) and her weight was 126 pounds (49<sup>th</sup> percentile). She reported a history of having difficulty manipulating objects in childhood, and was observed to have normal muscle tone and gross motor movements, but had a mild tremor at the end of intentional movements and mild difficulty with rapid alternating movements. Prior clinical testing for B03 included a normal karyotype (46, XX) and normal IQ. B02 was evaluated on the same occasion, was 50 years of age, and presented with a very similar clinical picture as his sister, B03. B01, the daughter of B02 and previously described to have mild dysarthria and a normal brain MRI (Guerreiro et al., 2000), was reported at 16 years of age to have intellectual disability but no speech disorder. A sister of B02 and B03 died at 16 months of age of unknown cause, and a maternal uncle never developed speech, had epilepsy and died in adulthood. Brain imaging was not available for either the deceased sister or uncle. B04, sister of B02 and B03, was unaffected. B05, the mother of B02 and B03, was unaffected and had a normal brain MRI (Guerreiro et al., 2000) and normal fluorescence *in situ* hybridization study of the DiGeorge syndrome region [ish 22q11.2 (TUPLE1x2)].

Family C is of Dutch descent and has a single male affected with unilateral perisylvian PMG and contralateral abnormal perisylvian sulcation with developmental motor and speech delay (Figures 1B and 1C). The proband has two healthy older sisters and healthy parents. He was born by induced delivery at 41 weeks gestation, following an uncomplicated pregnancy, and had a birth weight of 3.5 kg (46<sup>th</sup> percentile). In infancy, he was unable to breastfeed and learning to chew was slow and required therapy. He presented at 1 year of age with delay of motor development and hypotonia. A brain MRI was obtained at 2 years of age, noting right-sided perisylvian PMG, involving the posterior-frontal, anterior-parietal and postero-superior temporal lobes. The posterior body and isthmus of the corpus callosum was thin, the right cerebral ventricle was mildly enlarged and white matter volume was slightly diminished in the right hemisphere. At 3 years of age, his height is 93 cm (–1.5 standard deviations) and head circumference is 52.0 cm (0.8 standard deviations). He is noted to have a prominent forehead and downward-slanting eyelids. Neurologic examination revealed axial hypotonia and very mild left pyramidal signs but no differences in strength. Vision and hearing are normal; he sleeps well and has not had any seizures. At 3 years, he is able to stably walk and tries to jump and run, has good social skills but weak executive functions. Speech is delayed, as he uses two to three word sentences only, but oral motor abilities, including articulation, swallowing and chewing, are normal. He has a normal gag reflex and no mouth breathing.

Family D is of mixed European descent (Poland, Germany and Ireland) and has a single male affected with frontoparietal PMG, seizures, microcephaly, and neurodevelopmental delay (Figures 1B and 1C). The proband was born at 42 weeks gestation following an uncomplicated pregnancy and presented with seizures at 2 weeks of age. At 2 months of age, he had a normal head circumference and length (40<sup>th</sup> and 80<sup>th</sup> percentiles respectively by report), a small penis (< 10<sup>th</sup> percentile reportedly), was non-dysmorphic, exhibited hypotonia, had feeding difficulties and apneic episodes, as well as developmental delay (not smiling or rolling). Brain MRI at 2 months of age revealed extensive coarse PMG in the frontal and parietal lobes with subcortical calcifications and abnormal frontal white matter. A thin but fully formed corpus callosum was noted and the white matter was markedly diminished, especially frontally. Upon evaluation at 1 year, he had a mixed seizure disorder with complex and simple partial seizures described as occurring 1 per day initially, worsening when he was ill, and better controlled more recently. There was significant generalized hypotonia with spasticity and upper extremity hypertonia, and he did not have complete head control. He had oral motor discoordination (unable to bottle feed but able to breastfeed), recurrent otitis media and genu valgum that did not require intervention. Developmentally, he was rolling over at 1 year but did not fully grab, hold or transfer toys from his left to right hand; he said “ma” and responded to his name but did not fix or follow consistently. At that time he received physical, occupational and vision therapies. Head circumference

at 10 years 10 months was 49 cm (3.89 standard deviations below the mean). Ophthalmologic evaluation noted strabismus and significant cortical visual impairment with normal retina and optic nerves. At 11 years 8 months of age he has remained non-verbal, with dysphagia and mixed seizure disorder, hypotonia and severe global delay.

Family E is a non-consanguineous family from the United Arab Emirates and has a single female affected with bilateral frontoparietal PMG, microcephaly and severe global developmental delay (Figures 1B and 1C). The proband was born at full term following an unremarkable pregnancy and delivery, and her birth weight was 3 kg (21<sup>st</sup> percentile; -0.8 standard deviations). Hypotonia and developmental delay prompted a brain MRI at 5 months of age, which revealed bilateral PMG sparing the posterior temporal and occipital lobes; the cerebral ventricles were mildly enlarged and white matter volume slightly reduced. At 10 months of age, she had microcephaly; her head circumference was 40.7 cm (-3.2 standard deviations). At that time she was able to roll over but not sit or crawl, she had a palmar grasp only and had stereotyped movements. Neurologic evaluation revealed right esotropia, no response to visual or auditory stimuli, generalized hypotonia with head lag and normal deep tendon reflexes. At 13 months, she had not made further motor developmental progress but responded well to visual and auditory stimuli, and was social. She did not have seizures, though an EEG was reported to have shown bilateral synchronous epileptiform discharges but no medication was prescribed. Karyotype and serum lactic acid and ammonia levels were reported as normal. Another brain MRI was performed at 9 years of age that reported a thickened cortex bilaterally, shallow Sylvian fissures, slightly prominent cerebral ventricles, sparse white matter of normal signal intensity and minimally increased extra-axial cerebral spinal fluid. Follow-up evaluation at 13 years of age revealed spastic quadriplegia and global developmental delay. She was wheelchair bound, could roll over but not sit up or stand. She was nonverbal, had excessive drooling and feeding difficulties, taking soft and pureed foods orally with slow swallowing. Decreased range of motion, flexion deformity of the left wrist, equinus deformity of the left foot, and significant scoliosis with right curvature were noted. She was observed to be very attentive and smiling, and to both fix and follow appropriately. She was reported to menstruate, have urinary incontinence and have sleep disturbances.

Family F is of French Canadian, Russian and Irish descent and has a single female affected with unilateral right-sided PMG and seizures (Figures 1B and 1C). The proband has three siblings and a father who are healthy, and her mother has a history of thyroid adenoma and left frontal meningioma. She was born at term, had a birth weight of 4.9 kg (> 99<sup>th</sup> percentile, 3.2 standard deviations), and had an uncomplicated neonatal course. Seizures were first noted at 2 years of age and she had a history of motor developmental delay but normal speech and oral motor development. Her ability to reason and to comprehend others' language was reportedly reduced. Brain MRI at 21 years of age revealed right hemispheric PMG with the right hemisphere being smaller than the left, fully formed and thick corpus callosum, small right basal ganglia and thalamus, significant enlargement of the right lateral ventricle and severe diminution of the right hemispheric white matter. On evaluation at 28 years of age, she had macrocephaly with a head circumference of 60.5 cm (5.1 standard deviations), her height was 168 cm (77<sup>th</sup> percentile, 0.74 standard deviations), and her weight was 188 lbs (95<sup>th</sup> percentile, 1.7 standard deviations). Notably, her mother was also macrocephalic with a head circumference of 61 cm (6 standard deviations). Treated with Tegretol, a seizure frequency of once or twice a year was reported. She had good vision with normal visual field and extraocular movements.

## METHODS DETAILS

### Human genetics

Leukocyte-derived DNA was utilized for studies of all families. Genome-wide genotyping was performed on individuals 1-12 in Family A using the Illumina Infinium HumanHap550-Duo BeadChip. These data were used to perform linkage and haplotype analysis. Genotypes were called using GenomeStudio Software (Illumina). Low performing SNPs (those not called in all individuals in this study or not called in > 5% of individuals run on the same chips), low variance SNPs (those with minor allele frequencies (MAF) of 0 in all individuals in this study; or that have an MAF < 10% or that deviate from HWE with P value < 0.00000001 among unrelated individuals run on the same chips), and SNPs with Mendelian and non-Mendelian errors (calculated with Merlin) were removed from the analysis using PLINK. PLINK was used to thin SNPs to reduce linkage disequilibrium. Linkage analysis was performed to generate a LOD score from the remaining SNPs using Merlin under a dominant mode of inheritance assuming a disease allele prevalence of 0.0001 and a penetrance of 0.6. Haplotype analysis was performed on the SNPs around the maximum LOD score using Merlin. Whole exome sequencing (WES) was performed at the Broad Institute using Agilent Sure-Select Human All Exon v2.0 capture array and sequenced on Illumina HiSeq2000 sequencers.

### Identification and segregation of alleles

Linkage and haplotype analysis in Family A identified a candidate locus at Chromosome 2 (Figures S1B and S1C) with the highest LOD score of 2.48 at rs10930488-rs1489635; chr2:164,028,745-172,490,226 (hg19). Targeted sequencing was performed and the mutation identified in Family A is Chr2(GRCh37):g.165947387A>T, NM\_006922.3:c.5276T>A, p.Phe1759Tyr (Figure S1A). Algorithms suggest that the mutation is of a highly conserved nucleotide (phyloP: 5.29 [-14.1;6.4]), and predict the amino acid change to be deleterious [SIFT: deleterious (score: 0, median: 4.32), MutationTaster: disease-causing (p value: 1), PolyPhen-2: probably damaging (score: 1.0)]. The mutation identified in Family B is Chr2(GRCh37):g.165953971T>G, NM\_006922.3:c.4030A>C, p.Ile1344Leu. Algorithms suggest that the mutation is of a highly conserved nucleotide (phyloP: 5.21 [-14.1;6.4]), and predict the amino acid change to be deleterious [SIFT: deleterious (score: 0, median: 4.32), MutationTaster: disease-causing (p value: 1),

PolyPhen-2: possibly damaging (score: 0.88)]. The *de novo* mutation identified in Family C is Chr2(GRCh37):g.165987770A>G, NM\_006922.3:c.2549T>C, p.Leu850Pro. Algorithms suggest that the mutation is of a highly conserved nucleotide (phyloP: 5.13 [-14.1;6.4]), and predict the amino acid change to be deleterious [SIFT: Deleterious (score: 0, median: 4.32), MutationTaster: disease-causing (p value: 1), PolyPhen-2: probably damaging (score: 0.999). The *de novo* mutation in Families D and E is Chr2(GRCh37):g.165986748A>G, NM\_006922.3:c.2624T>C, p.Ile875Thr. Algorithms suggest that the mutation is of a highly conserved nucleotide (phyloP: 4.89 [-14.1;6.4]), and predict the amino acid change to be deleterious [SIFT: Deleterious (score: 0.01, median: 4.32), MutationTaster: disease causing (p value: 1), PolyPhen2: probably damaging (score: 1.0)]. I875 was previously reported in two large intellectual and developmental disability cohorts, ClinVar ID 373960 (Deciphering Developmental Disorders Study, 2017; Lelieveld et al., 2016). The mutation in Family F is Chr2(GRCh37):g.165997318C>T, NM\_006922.3:c.1862G>A, p.Arg621His. Algorithms suggest that the mutation is of a highly conserved nucleotide (phyloP: 4.48 [-14.1;6.4]), and predict the amino acid change to be deleterious [SIFT: Deleterious (score: 0, median: 4.32), MutationTaster: disease causing (prob: 1), PolyPhen2: probably damaging (score: 0.99)].

Sanger sequencing confirmed familial segregation of the inherited mutations in Family A and B, and the *de novo* occurrence of the mutations in Family C, D, and E, being absent from both parents (Figures S1F and S1H). In Family F, the mutation was confirmed by Sanger sequencing in the proband and was absent from her mother but DNA was not available from the father to verify its *de novo* occurrence (Figure S1G). Further, amino acids upstream and downstream of R621, L850, I875, I1344 and F1759 in SCN3A are highly conserved in orthologs as well, 16 of 20 amino acids, 19 of 20 amino acids, 19 of 20 amino acids, 20 of 20 amino acids, and 20 of 20 amino acids respectively (Figures S1D–S1H). Taken together, these data demonstrate that the SCN3A gene and the families' mutation sites and surrounding alleles are highly conserved.

### Electrophysiology

Neurons were visualized using an inverted Olympus IX73 microscope with epifluorescence capabilities. Whole-cell voltage-clamp currents (series resistance compensated 85%) were recorded with an Axopatch 200B amplifier and pClamp 9.2 (Molecular Devices, Sunnyvale, CA). Glass pipettes were formed from borosilicate glass (1.5–3 Mohm) on a Sutter Puller (P-97 Sutter Instrument) and filled with intracellular solution for voltage clamp (in mM: 80 CsMES, 25 NaCl, 10 HEPES, 10 Cs4-BAPTA, 2 MgCl<sub>2</sub>, free Ca 90uM, OsM 295 mOs. pH 7.3 with CsOH) or for current clamp (in mM: 120 K-gluconate, 10 Na-gluconate, 4 NaCl, 10 HEPES-K, 10 Na phosphocreatine, 2 Na-ATP, 4 Mg-ATP, and 0.3 GTP, adjusted to pH 7.3 with KOH). Control extracellular solution contained the following (in mM): 150 NaCl, 10 HEPES, 1.8 CaCl<sub>2</sub>, pH to 7.4 with NaOH, 300mOsM.

HEK293T cells (from ATCC, CRL-3216) were grown under standard culture conditions (5% CO<sub>2</sub>, 37°C) in Dulbeccos's Modified Eagle's Medium with 10% FBS and antibiotics. The sex of the cell line was undetermined. Site directed mutagenesis of SCN3A-F1759Y and SCN3A-I875T was performed using a bridge PCR method followed by Sanger sequencing of the entire plasmid to control for off-target mutations. Cells were transfected (Lipofectamine 3000, ThermoFisher) with one of the SCN3A alpha subunits: SCN3A-WT, SCN3A-F1759Y, or SCN3A-I875T, together with the human auxiliary Na<sub>v</sub>-Beta subunits (β1-IRES-CD4 and β2-IRES-GFP; using a plasmid ratio of 1:6 for β:SCN3A) to support membrane localization and physiological current kinetics. Data were analyzed with Igor-Pro (Wavemetrics) and reported as mean ± SEM. Conductance-voltage plots (from measured reversal potentials) were fit with a Boltzmann function of the following form ( $I_{max}/(1+\exp[(V-V_{half})/k_s])$ ), where  $I_{max}$  is the maximal current,  $V$  is the pre-pulse potential,  $V_{half}$  is the half activation potential of the current, and  $k_s$  is the slope factor. Statistical significance was assessed with Student's two-tailed t test. For measuring the non-inactivating persistent current ( $I_{NaP}$ ), the mean current from the last 30 ms of the voltage step was measured and this value was divided by the maximal peak inward current. These  $I_{NaP}$  data are presented as a percentage of the maximal peak inward current.

### Human tissue brain preparation and mRNA *in situ* hybridization

Following fixation (4% PFA) and cryoprotection (30% sucrose), brains (17–20 gestational weeks, both male and female) were frozen using Isopentane on dry ice. Samples were sectioned at 20–30 μm thickness (Leica Cryostat), mounted immediately onto warm charged SuperFrost Plus slides (Fisher), then dried at –20°C for 20 min before storage at –80°C. After applying a hydrophobic barrier around the tissue (ImmEdge Pen, Vector Labs), sections were baked for 20 min at 60°C before beginning with the manufacturer's standard protocol for multiplex fluorescent *in situ* hybridization (Multiplex Version 2 kit, Advanced Cell Diagnostics). *In situ* probe ACD catalog numbers are as follows: *Vimentin*: 479411, *SCN3A*: 460121, *GFAP*: 311801, *RBFOX*: 415591, *Eomes*: 429691. Whole tissue mRNA *in situ* imaging was performed on a Zeiss Axio Observer with image tiling at 20X magnification. Bright-field images were background corrected by Zen Blue Software for center intensity illumination and stitched together (Figures 3C and 3D).

### Ferret *in utero* electroporation

All animal experimentation was carried out under protocols approved by the Institutional Animal Care and Use Committee (IACUC) of Boston Children's Hospital. Ferrets (*Mustela putorius furo*) were obtained from Marshall Bioresources and animals were same-sex housed within a dedicated Large Animal Facility of Boston Children's Hospital on a 12-hr light/dark cycle at 18°C–23°C, with rotating sensory enrichment. Food and water were available *ad libitum*. *In utero* electroporations were performed according to standard procedures (Kawasaki et al., 2012). Briefly, pregnant Jills (embryonic day 32–33) were anesthetized with 5% isoflurane and maintained at 3% utilizing a nose cone. Following laparotomy, 1.5–3 μL (2 μg/μl) of the SCN3A and mCherry constructs were introduced into the

lateral ventricle using a pulled glass micropipette and Hamilton syringe (Hamilton Company). 150V square electric pulses were passed 5 times at 1 s intervals (ECM830, BTX). Tissues were harvested on postnatal days P0 and ~P33, and fixed in 4% PFA. Successful plasmid expression in embryos was evaluated based on mCherry fluorescence (Figure S4B). Both male and female embryos were targeted for injection.

### Ferret tissue preparation and immunohistochemistry

Following perfusion with ice cold 4% PFA in PBS, tissues were drop-fixed for 8 hours in 4% PFA at 4°C. For cryosections, brains were cryoprotected in 30% sucrose overnight, embedded in OCT, frozen in isopentane, sectioned at 15–35  $\mu$ m thickness (Leica Cryostat), and mounted onto charged SuperFrost Plus slides (Fisher). After applying a hydrophobic barrier around the tissue (ImmEdge Pen, Vector Labs), slides were washed in cold 0.1M PB followed by antigen retrieval and endogenous fluorescence quenching (Retrievagen A pH6.0, BD Biosciences) at 80–90°C in a hybridization oven for 45 min. Sections were then cooled to room temperature in Retrievagen A, washed in cold 0.1M PB, and blocked for 1 hour at room temperature (5% Normal Donkey Serum, 1% w/v BSA, 0.2% w/v each glycine/lysine, in PBS). Slides were incubated with primary antibodies for two nights on a rotary shaker at 4°C in blocking buffer plus 0.3% Triton X-100, washed in PBS, and incubated for two hours at room temperature with secondary antibodies diluted in blocking buffer (1:500; Jackson Immunoresearch). Finally, slides were washed in PBS, and coverslipped with Fluoromount-G containing Dapi (Southern Biotech). Images were obtained with a Zeiss LSM700 confocal microscope and Leica MZ16 F fluorescence stereomicroscope. Primary antibodies include mouse anti-phosphorylated Vimentin (4A4; 1:500; MBL), rabbit anti-Ki67 (1:250; Abcam ab15580), chicken anti-GFAP (1:1000; Abcam ab4674), mouse anti-TUJ1 (beta-III tubulin; 1:500; Abcam ab7751), rabbit anti-RFP (1:250; Rockland 600-901-379S), rabbit anti-SATB2 (1:400; Bethyl A301-864A). Secondary antibodies included AlexaFluor (1:500; 488nm, 563nm, 650nm) donkey anti-mouse and donkey anti-rabbit (Invitrogen).

### Membrane protein extraction and immunoblotting

HEK293T cells were harvested and membranes were isolated according to manufacturer's instructions (Mem-PER Plus Membrane Protein Extraction Kit for Mammalian Cells, Thermo Fisher Scientific). Membrane proteins (25ug) were resolved on 4%–15% SDS-polyacrylamide gels (Bio-Rad), transferred to PVDF membrane (GE Healthcare Life Science), and probed with rabbit anti-Pan Na Channel  $\alpha$  Subunit (clone D219C, 1:1000, Cell Signaling Technology), mouse anti-ATP1A1 (clone 464.6, 1:1000, Thermo Fisher Scientific), and chicken anti-GFP (1:1000, Abcam) antibodies, followed by anti-rabbit or anti-mouse horseradish peroxidase secondary antibodies (1:2000, Cell Signaling Technology). Immunoblots were developed with the Amersham ECL Western Blotting Detection Kit (GE Healthcare Life Science).

## QUANTIFICATION AND STATISTICAL ANALYSIS

### Quantitative MRI analysis

The MRI images (B03 and control age-matched subject) were processed to extract the surfaces of the gray/white matter and gray matter/cerebrospinal fluid boundaries, and to define Brodmann areas on the cortical surface using FreeSurfer software.

### Human gene expression analysis

The Allen Human Brain Atlas (ABA) publishes a rich dataset of cortical genetic expression across cortical brain regions, from age 8 weeks post conception to adult ages (Jones et al., 2009). BrainSpan data analysis of *SCN3A* (ch2:165944030-166060577, GRCh37/hg19) and *SCN1A* (ch2: 166,845,670-166,930,180, GRCh37/hg19) was performed. RNA-seq expression measured in RPKM (reads per kilobase exon per million mapped reads) was obtained from the BrainSpan project data and summarized to Genecode v10 exons for all annotated neocortical tissues aged 8 weeks post conception to 38 years. Cortical areas for Figure 3A include: dorsolateral prefrontal cortex; ventrolateral prefrontal cortex; anterior (rostral) cingulate (medial prefrontal) cortex; orbital frontal cortex; primary motor-sensory cortex; parietal neocortex; posterior (caudal) superior temporal cortex (area 22c), inferolateral temporal cortex (area 20); occipital neocortex.

### Analysis of single cell RNA-seq data

Dataset was provided by Alex Pollen UCSF; see (Pollen et al., 2015) methods for additional information. Briefly, fetal cortex was dissociated and captured on C1 (Fluidigm). Classification of cells was completed using principal component analysis (PCA) and used expectation-maximization clustering to group cells based on their position in PC space. Gene expression values were normalized based on library size as counts per million reads (CPM) and  $\log_2(\text{CPM}+1)$  transformed. Libraries with fewer than 1,000 genes detected above 1 CPM were eliminated as outliers. Since these data contain many cells with zero CPM for the genes of interest, either due to lack of expression or to the limits of detection of single cell RNA-seq, a two-part Wilcoxon test was used to test differences in gene expression. A compound null hypothesis of no difference in the proportion of cells with zero CPM and of no difference in the mean CPM of the non-zero CPM cells for a given gene between two groups was tested. An R code, which applies a two-part Wilcoxon test with a continuity-corrected binomial test was implemented. These tests were conducted with a Bonferroni adjusted alpha level of 0.017 (0.05/3). Data are presented as box-plots.



### Primary neuronal cultures and neurite analysis

Neuronal cultures were prepared according to established protocols with modifications. Briefly, the perisylvian cortex was dissected from 19–20 WKSG human samples, male and female cases, and dissociated according to the manufacturer's protocol into a single cell suspension (MACs neural dissociation kit, Miltenyi Biotec). Cortical neurons were plated onto poly-ornithine and laminin treated coverslips at  $5 \times 10^4$  cells/well in 24-well plates and maintained in DMEM/Neurobasal, N2, B27, glucose, NaHCO<sub>3</sub>, HEPES (4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid) with fibroblast growth factor 2 (FGF-2; 20 ng/mL; Invitrogen) and EGF (FGF-2; 20 ng/mL; Invitrogen) treatment for the first 24 h only. Neurons were transfected with mCherry vector together with each experimental condition at a 1:6 plasmid ratio as described above (Figure S2). Cultured medium was changed every other day. Neurons were fixed after 5 days *in vitro* (DIV 5) with 4% PFA in PBS for 15 min. at room temperature. Cells were blocked in 10% NGS in PBS with 0.3% Triton X-100 for 1 h at room temperature followed by immunostaining. Images were captured using a digital camera under a Zeiss Axio Observer fluorescent microscope. 30–50 neurons were analyzed from three separate coverslips for each experimental condition. Neurites that had lengths at least twice the diameter of the cell body were measured. Neurite lengths from the soma were traced and measured using ImageJ software in a blinded manner, and data were analyzed using Igor Pro Software. Statistical significance was assessed with Student's two-tailed t test.

### Ferret brain magnetic resonance imaging

Three P30 ferret brains (expressing *SCN3A*-WT, *SCN3A*-F1759Y, and mCherry) were post-fixed in 4% paraformaldehyde in PBS and submerged into perfluorocarbon oil (Fomblin, Fisher Scientific) at 4°C for 3 days. The brains were scanned using a Bruker BioSpec 70/30 7T MRI scanner (Small Animal Imaging Laboratory) at BCH. This is a high-resolution (sub-millimeter) MRI scanner designed specifically for imaging small animals, and has a 30 cm bore and 450 mT/m gradient. Ferret MRI scans are isotropic 63  $\mu$ m voxels across the entire brain. Cortical gray matter and white matter were visualized using the FreeSurfer and OsiriX software.

### DATA AND SOFTWARE AVAILABILITY

The accession numbers for sequencing data generated in the manuscript GEOI: phs000492.v3.p1.